IVERIC bio, Inc. (NASDAQ:ISEE) Holdings Reduced by Citigroup Inc.

Citigroup Inc. decreased its position in IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) by 64.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 179,348 shares of the company’s stock after selling 329,698 shares during the period. Citigroup Inc.’s holdings in IVERIC bio were worth $3,840,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Captrust Financial Advisors grew its position in IVERIC bio by 14,900.0% in the 1st quarter. Captrust Financial Advisors now owns 1,500 shares of the company’s stock worth $25,000 after purchasing an additional 1,490 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in shares of IVERIC bio by 679.5% in the second quarter. Macquarie Group Ltd. now owns 8,005 shares of the company’s stock valued at $77,000 after acquiring an additional 6,978 shares in the last quarter. Great West Life Assurance Co. Can bought a new position in shares of IVERIC bio in the third quarter valued at approximately $85,000. Royal Bank of Canada boosted its holdings in shares of IVERIC bio by 177.2% in the third quarter. Royal Bank of Canada now owns 8,792 shares of the company’s stock valued at $158,000 after acquiring an additional 5,620 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of IVERIC bio in the third quarter valued at approximately $203,000.

Insiders Place Their Bets

In other IVERIC bio news, CFO David Francis Carroll sold 63,500 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $37.04, for a total value of $2,352,040.00. Following the completion of the sale, the chief financial officer now owns 68,472 shares in the company, valued at approximately $2,536,202.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, COO Keith Westby sold 20,000 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $37.12, for a total transaction of $742,400.00. Following the transaction, the chief operating officer now owns 39,652 shares in the company, valued at approximately $1,471,882.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David Francis Carroll sold 63,500 shares of the stock in a transaction on Monday, May 1st. The stock was sold at an average price of $37.04, for a total transaction of $2,352,040.00. Following the transaction, the chief financial officer now owns 68,472 shares in the company, valued at approximately $2,536,202.88. The disclosure for this sale can be found here. Insiders sold a total of 213,500 shares of company stock worth $6,752,471 in the last quarter. 2.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ISEE shares. Stifel Nicolaus cut shares of IVERIC bio from a “buy” rating to a “hold” rating in a report on Friday, May 5th. Credit Suisse Group cut shares of IVERIC bio from an “outperform” rating to a “neutral” rating in a report on Monday, May 1st. Wedbush cut shares of IVERIC bio from an “outperform” rating to a “neutral” rating in a report on Monday, May 1st. Guggenheim cut shares of IVERIC bio from a “buy” rating to a “neutral” rating in a report on Monday, May 1st. Finally, Robert W. Baird cut shares of IVERIC bio from an “outperform” rating to a “neutral” rating in a report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.45.

IVERIC bio Stock Performance

Shares of NASDAQ:ISEE opened at $36.90 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.53 and a current ratio of 15.53. IVERIC bio, Inc. has a 52 week low of $8.85 and a 52 week high of $38.25. The firm has a 50 day simple moving average of $29.95 and a 200 day simple moving average of $24.31.

IVERIC bio (NASDAQ:ISEE – Get Rating) last released its earnings results on Wednesday, March 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.10). During the same period in the prior year, the firm posted ($0.29) EPS. Research analysts forecast that IVERIC bio, Inc. will post -1.76 EPS for the current fiscal year.

IVERIC bio Profile

(Get Rating)

IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.